Skip to content

How NF1 Evolves: Symptoms and Progression

Last updated:

Neurofibromatosis Type 1 (NF1) is a genetic condition with symptoms that evolve over a lifetime. Early signs include café-au-lait spots in infancy, followed by learning challenges and eye changes in childhood, and cutaneous neurofibromas or vascular issues during adulthood.

Key Takeaways

  • NF1 symptoms vary greatly in severity and timing from person to person, even among family members with the exact same genetic mutation.
  • Infants and young children typically first present with skin changes like café-au-lait spots and skeletal differences such as tibial bowing.
  • School-aged children with NF1 require regular monitoring for learning difficulties, ADHD, and benign eye tumors called optic pathway gliomas.
  • During puberty and adulthood, hormonal changes often trigger the development of benign, pea-sized skin bumps called cutaneous neurofibromas.
  • Lifelong routine screening is essential to catch and manage rare but serious complications like severe high blood pressure or malignant tumor changes.

Neurofibromatosis Type 1 (NF1) is described by doctors as having variable expressivity [1]. This means that while two people may have the exact same genetic mutation—even within the same family—their symptoms, the severity of those symptoms, and when they appear can be very different [1][2].

Because NF1 affects the way cells grow throughout the body, it is a multisystem condition, meaning it can impact the skin, bones, brain, and blood vessels [3]. Understanding how these symptoms typically evolve over a lifetime can help you and your medical team stay ahead of your or your child’s needs.

Infancy and Early Childhood (Ages 0–5)

In the earliest years, NF1 is primarily identified through skin and bone findings.

  • Café-au-lait macules (CALMs): These flat, light-brown birthmarks are often the very first sign of NF1 [4]. While some babies are born with them, more usually appear during the first year of life [4][5].
  • Plexiform neurofibromas (pNFs): These are complex tumors that grow along nerves [6]. Unlike other types of neurofibromas, pNFs are often present at birth or develop in early childhood [7]. They can sometimes be felt as a soft mass under the skin, or you might notice asymmetric growth, such as one arm or leg appearing thicker or longer than the other [7].
  • Tibial Dysplasia: A rare but significant early sign is a bowing of the lower leg bone (tibia) [8]. If left untreated, this can lead to a “false joint” or pseudarthrosis, where the bone does not heal properly after a fracture [8].

School-Age Children (Ages 6–12)

As children enter school, the focus often shifts toward neurological and cognitive development.

  • Cognitive and Learning Challenges: Many children with NF1 experience difficulties with executive function, which includes planning, working memory, and staying organized [9]. Up to 50% of children with NF1 may have ADHD (Attention-Deficit/Hyperactivity Disorder) [10]. Additionally, up to 30-40% may exhibit traits of Autism Spectrum Disorder (ASD), making early screening for both conditions just as important [10].
  • Optic Pathway Gliomas (OPGs): These are benign (non-cancerous) tumors that grow on the nerves connecting the eyes to the brain [2]. Most OPGs are found in children under age 7 and often do not cause symptoms, but they require regular eye exams [2][11]. Watch for visual ‘red flags’ between appointments, such as a bulging eye (proptosis), noticeable squinting, or a child complaining about their vision [2].
  • Skinfold Freckling: Small freckles in the armpits or groin typically begin to appear during these years [4].

Adolescence and Adulthood (Ages 13+)

During puberty and into adulthood, new physical changes may occur, and monitoring for rare complications becomes more important.

  • Cutaneous Neurofibromas (cNFs): These are small, pea-sized bumps on or just under the surface of the skin [6]. They can increase in number during puberty or pregnancy due to hormonal changes [12][7]. While they are benign, the development of visible tumors can take a massive emotional and mental health toll, significantly impacting body image and quality of life [6].
  • Vascular Issues and Hypertension: NF1 can affect the walls of blood vessels (vasculopathy), which may lead to high blood pressure (hypertension) [13][3]. In children and teens, a condition called renal artery stenosis (narrowing of the arteries to the kidneys) is a primary cause of severe high blood pressure [13]. Regular blood pressure monitoring is vital throughout life.
  • Rare Complications:
    • Pheochromocytoma: A very rare, usually benign tumor of the adrenal gland that can cause high blood pressure and headaches, mostly presenting in adulthood [14].
    • MPNST: A very small percentage (about 8–13%) of plexiform neurofibromas can transform into a malignant peripheral nerve sheath tumor (MPNST), which is cancerous [15][16]. Doctors watch for “red flags” like constant, severe pain or a tumor that suddenly grows rapidly [15].
System Infancy/Early Childhood School-Age Adolescence/Adulthood
Skin Café-au-lait spots Freckling in folds Cutaneous neurofibromas
Neurological Plexiform neurofibromas ADHD, ASD, learning issues Monitoring for MPNST
Vision Early OPG monitoring Lisch nodules (eye spots) Continued eye health
Skeletal Tibial bowing Scoliosis (spine curve) Bone density monitoring
Vascular - Blood pressure checks Vasculopathy/Pheochromocytoma

Frequently Asked Questions

When do the first signs of NF1 usually appear?
The first signs of NF1 typically appear during infancy or early childhood. These most commonly include flat, light-brown birthmarks called café-au-lait spots and complex nerve tumors known as plexiform neurofibromas.
Can NF1 affect my child's learning and development?
Yes, many children with NF1 experience learning challenges, particularly with organization and working memory. Rates of ADHD and traits of Autism Spectrum Disorder are also significantly higher, making early screening very important for getting the right support in school.
What are the warning signs of an optic pathway glioma in NF1?
Optic pathway gliomas are typically benign tumors that grow on the nerves connecting the eyes to the brain. Parents should watch for visual red flags between eye exams, such as a bulging eye, noticeable squinting, or the child complaining about their vision.
Why does blood pressure need to be monitored closely with NF1?
NF1 can affect your blood vessels, which can lead to severe high blood pressure. In children, this is often caused by narrowed arteries to the kidneys, while adults may rarely develop an adrenal gland tumor called a pheochromocytoma.
When should I call the doctor about an NF1 tumor?
You should contact your doctor immediately if you experience constant, severe pain or notice that a tumor suddenly begins growing rapidly. These can be warning signs of a rare complication that requires prompt medical evaluation.

Questions for Your Doctor

  • Which symptoms of NF1 should I expect to see first, and what is the typical timeline for others to appear?
  • How often should I or my child have vision and blood pressure checked to monitor for NF1-related changes?
  • If I or my child struggle with focus or schoolwork, how do we determine if it's related to ADHD or ASD, and what support is available?
  • Are there specific 'red flag' signs, like persistent pain or rapid growth of a bump, that should prompt an immediate call to your office?
  • Do I or my child have any skeletal markers, like bowing of the legs, that require a consultation with an orthopedic specialist?

Questions for You

  • Have you noticed any new light-brown spots or freckling in areas like the armpits or groin since the last check-up?
  • Do you or your child seem to struggle more with certain tasks at school or work, such as following multi-step directions or finishing timed assignments?
  • Have you noticed any changes in coordination, balance, or walking patterns?
  • How are you feeling about managing the different aspects of care? What area (skin, school, physical health) feels most pressing right now?

Want personalized information?

Type your question below to get evidence-based answers tailored to your situation.

References

  1. 1

    Human iPSC-Derived Neurons and Cerebral Organoids Establish Differential Effects of Germline NF1 Gene Mutations.

    Anastasaki C, Wegscheid ML, Hartigan K, et al.

    Stem cell reports 2020; (14(4)):541-550 doi:10.1016/j.stemcr.2020.03.007.

    PMID: 32243842
  2. 2

    Orthopaedic manifestations of neurofibromatosis type 1: A case report.

    Năstase F, Radaschin DS, Niculeț E, et al.

    Experimental and therapeutic medicine 2022; (23(2)):135 doi:10.3892/etm.2021.11058.

    PMID: 35069816
  3. 3

    Neurofibromatosis -1 diagnosed from an intraoral swelling - a case series.

    Fahy E, Mulvihill C, O'Donoghue G, et al.

    Australian dental journal 2021; (66(2)):205-211 doi:10.1111/adj.12797.

    PMID: 32990942
  4. 4

    [Translated article] Neurofibromatosis Type 1: Diagnostic Timelines in Children.

    García-Martínez FJ, Hernández-Martín A

    Actas dermo-sifiliograficas 2023; (114(3)):T187-T193 doi:10.1016/j.ad.2022.10.043.

    PMID: 36717073
  5. 5

    Café-Au-Lait Macules in Neurofibromatosis Type 1: Birthmark or Biomarker?

    Santangelo A, Chelleri C, Tomasino M, et al.

    Cancers 2025; (17(9)) doi:10.3390/cancers17091490.

    PMID: 40361417
  6. 6

    Integrative Analysis Identifies Candidate Tumor Microenvironment and Intracellular Signaling Pathways that Define Tumor Heterogeneity in NF1.

    Banerjee J, Allaway RJ, Taroni JN, et al.

    Genes 2020; (11(2)) doi:10.3390/genes11020226.

    PMID: 32098059
  7. 7

    The NF1 microdeletion syndrome: early genetic diagnosis facilitates the management of a clinically defined disease.

    Kehrer-Sawatzki H, Bäzner U, Krämer J, et al.

    Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG 2022; (20(3)):273-277 doi:10.1111/ddg.14707.

    PMID: 35246941
  8. 8

    Neurofibromatosis type 1.

    Anderson JL, Gutmann DH

    Handbook of clinical neurology 2015; (132()):75-86.

    PMID: 26564071
  9. 9

    Comprehensive approach of executive functions in children with neurofibromatosis type 1.

    Remaud J, Guerra A, Beaussart-Corbat ML, et al.

    Neuropsychology 2025; (39(4)):332-346 doi:10.1037/neu0000995.

    PMID: 40244956
  10. 10

    Editorial: Understanding the Nature of Attention Problems in Neurofibromatosis Type 1: Clinical and Research Implications.

    Vogel AC

    Journal of the American Academy of Child and Adolescent Psychiatry 2025; (64(4)):419-420 doi:10.1016/j.jaac.2024.12.005.

    PMID: 39722341
  11. 11

    Neurofibromatosis type 1 - an update.

    Moodley M, Lopez KR

    Seminars in pediatric neurology 2024; (52()):101172 doi:10.1016/j.spen.2024.101172.

    PMID: 39622609
  12. 12

    The effect of pregnancy on growth-dynamics of neurofibromas in Neurofibromatosis type 1.

    Well L, Jaeger A, Kehrer-Sawatzki H, et al.

    PloS one 2020; (15(4)):e0232031 doi:10.1371/journal.pone.0232031.

    PMID: 32343738
  13. 13

    Was the internal thoracic arterial graft selection for coronary artery bypass grafting appropriate in a patient with neurofibromatosis-1?

    Nakayama T, Nakayama M, Harada T, et al.

    SAGE open medical case reports 2019; (7()):2050313X18818724 doi:10.1177/2050313X18818724.

    PMID: 30719296
  14. 14

    Screening for Hereditary Pheochromocytoma in a Patient with Neurofibromatosis Type 1: A Case Report.

    Ferreira Barros II, Manso F, Caldas E Silva AI, Silva Lopes Pereira MR

    TouchREVIEWS in endocrinology 2021; (17(1)):79-82 doi:10.17925/EE.2021.17.1.79.

    PMID: 35118451
  15. 15

    Image-Based Differentiation of Benign and Malignant Peripheral Nerve Sheath Tumors in Neurofibromatosis Type 1.

    Liu J, Huang JN, Wang MH, et al.

    Frontiers in oncology 2022; (12()):898971 doi:10.3389/fonc.2022.898971.

    PMID: 35677169
  16. 16

    From benign neurofibromas to malignant peripheral nerve sheath tumors (MPNST): a gaming among multiple factors.

    Yu Y, Wei C, Yue M, et al.

    Cellular oncology (Dordrecht, Netherlands) 2025; (48(4)):841-857 doi:10.1007/s13402-025-01054-9.

    PMID: 40172801

This page provides an educational overview of typical NF1 progression. It does not replace professional medical advice. Always consult your healthcare provider or genetics team about specific symptoms or changes you observe.

Stay up to date

Get notified when new research about Neurofibromatosis type 1 is published.

No spam. Unsubscribe anytime.